GLP
Global Partners LP
Latest price
As of Oct 26, 2026, 7:00 PM EDT · Market data by Massive
Market cap
$1.6B
Volume
37.4K
Previous close
$48.44
Day range
$48.06 – $48.81
Listed
Sep 29, 2005
Coverage
8 articles
Price performance
Recent trading
Newsroom
Latest GLP coverage
Eli Lilly Stock Climbs as GLP-1 Demand Fuels Higher Sales Outlook
Eli Lilly (LLY) shares surged on Wednesday after the pharmaceutical giant raised its full-year sales forecast and delivered second-quarter results that beat expectations.
Hims & Hers Stock Jumps on FDA Signals, but Regulatory Risks Still Loom for Investors
Hims & Hers (HIMS) extended its rally this week, surging for a second straight session as investors reacted to signals that U.S. regulators may take a more flexible approach toward certain peptide treatments.
Hims & Hers Dives on FDA Crackdown, Sending Shockwaves Through Weight-Loss Drug Trade
Hims & Hers (HIMS) took a steep dive after U.S. regulators signaled an aggressive move against compounded versions of blockbuster weight-loss medicines, shaking investor confidence in one of the fastest-growing corners of digital health.
Stock Market Today: Dow, S&P 500, Nasdaq Slip as Investors Brace for Major Fed Rate Decision
US stocks fell on Monday as Wall Street entered a pivotal week dominated largely by expectations for a Federal Reserve rate cut.
Stock Market Today: Stocks Climb as Earnings Pour In, Auto Tariff Relief Hopes Boost Optimism
Stocks moved higher on Tuesday as investors digested a wave of corporate earnings and looked to the White House for signs of relief from burdensome auto tariffs.
Stock Market Today: Dow Plunges Over 500 Points as UnitedHealth Tanks; S&P and Nasdaq End Flat
Stocks wrapped a volatile shortened trading week with mixed performances on Thursday as a sharp sell-off in UnitedHealth dragged the Dow deep into the red.
Stock Market Today: Stock Market Sees Downturn Amid Tariff Worries and Rising Inflation Fears
As of midday Tuesday, US stocks struggled as all three major indices fell. Investor sentiment was weighed down by President Trump's tariff comments and worsening consumer confidence.
Major CVD event risk cut by 20% in adults without diabetes, with overweight or obesity
[ad_1] Research Highlights: In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight. Semaglutide is a GLP-1 medication primarily ...